ReviewDisease markers2021
ECG Markers of Cardiovascular Toxicity in Adult and Pediatric Cancer Treatment.
Review in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Risk-Adaptive Cardio-Oncology Rehabilitation: A Narrative Review of Exercise Prescription, Multimodal Monitoring, and Implementation Pathways.Healthcare (Basel, Switzerland) · 2026Review
- Wearable technologies in clinical trials for drug development: trends and emerging opportunities.Nature reviews. Drug discovery · 2026Review
- Early electrocardiographic changes associated with anticancer chemotherapy in a Sub-Saharan African population: a prospective cohort study.BMC cancer · 2026Article
- Zebrafish Model Reveals Early Electrocardiographic and Molecular Signatures of Doxorubicin-Induced Cardiotoxicity.Cardiovascular toxicology · 2026Article
- Doxorubicin-Induced Cardiac Remodeling: Mechanisms and Mitigation Strategies.Cardiovascular drugs and therapy · 2026Review
- Cardiotoxicity associated with anticancer therapies for gynecological tumors.Frontiers in cardiovascular medicine · 2026Review
- Endocrine and cardiovascular consequences of plasticiser exposure: a narrative review from the thyroid- cardiac axis perspective.Frontiers in pharmacology · 2026Review
- Nanomedicine-Based Strategies for Mitigating Chemo/Radiotherapy-Induced Cardiac Inflammation and Fibrosis.Cardiovascular toxicology · 2025Review
- Urolithin A-laden functional nanoparticles alleviate cisplatin-induced cardiotoxicity in mice by inhibiting inflammation-induced lymphangiogenesis.Free radical biology & medicine · 2025Article
- Cardioprotective strategies in the management of chemotherapy-induced cardiotoxicity: current approaches and future directions.Annals of medicine and surgery (2012) · 2024Review
- The Effects of Pediatric Acute Lymphoblastic Leukemia Treatment on Cardiac Repolarization.Children (Basel, Switzerland) · 2024Article
- Post-transplant cyclophosphamide-induced cardiotoxicity: A comprehensive review.Journal of cardiovascular and thoracic research · 2024Review
- Cardiac electrical abnormalities in childhood acute lymphoblastic leukemia survivors: a systematic review.Cardio-oncology (London, England) · 2023Review
- Association of atrial fibrillation and outcomes in patients undergoing bone marrow transplantation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023Article
- Electrocardiographic features of children with Duchenne muscular dystrophy.Orphanet journal of rare diseases · 2022Review
- Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy.Frontiers in cardiovascular medicine · 2022Review
- Consumer Wearables and the Integration of New Objective Measures in Oncology: Patient and Provider Perspectives.JMIR mHealth and uHealth · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When a cardiologist is asked to evaluate the cardiac toxic effects of chemotherapy, he/she can use several tools: ECG, echocardiography, coronary angiography, ventriculography, and cardiac MRI. Of all these, the fastest and easiest to use is the ECG, which can provide information on the occurrence of cardiac toxic effects and can show early signs of subclinical cardiac damage. These warning signs are the most desired to be recognized by the cardiologist, because the dose of chemotherapeutics can be adjusted so that the clinical side effects do not occur, or the therapy can be stopped in time, before irreversible side effects. This review addresses the problem of early detection of cardiotoxicity in adult and pediatric cancer treatment, by using simple ECG recordings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.